However, a RAF/MEK inhibitor has recently shown activity across a wide range of solid tumors and multiple myeloma.24 With the growing list of biomarker-based drug approvals, it is expected that genomics-informed therapies will play a significant role in patients with metastatic cancer.1 The gene discussed is MAP2K7; the disease is plasma cell myeloma.